Jeronselvain, Lecture on 'Selveinju' at the Korean Neurosurgical Society Academic Conference

Specialized pharmaceutical manufacturer Jeron Selvein announced on the 20th that it officially introduced the prescription drug ‘Selvein Injection,’ a pain and inflammation treatment, as a speaker at the Korean Neurosurgical Society Spring Scientific Meeting.

The ‘2025 Korean Neurosurgical Society Spring Scientific Meeting,’ held on the 16th at Sejong University Gwanggaeto Hall Convention Center by the Korean Neurosurgical Society, was attended by over 600 participants who shared the latest insights.

At this conference, Kim Deok-gyu, CEO of Jeron Selvein, gave a presentation titled ‘Is PDRN a Panacea?’ covering △ the mechanism of PDRN △ application areas by product △ medical treatment fields △ Jeron Selvein’s patented technology.

Jeron Selvein’s patented technology, ‘Prism Technology (Prism-T),’ is a proprietary method for producing nucleic acid fragments of uniform size. By manufacturing products with small and uniform molecules of consistent size, it achieves up to five times smaller molecular weight than existing PDRN, resulting in superior absorption quantity and efficiency in the body.

Kim Deok-gyu, CEO of Jeron Selvein, stated, “We expect it to be widely utilized not only for pain and spinal diseases in neurosurgery but also in various clinical applications. Based on excellent quality and safety, it will become an important treatment option that meets patients’ needs.”

He added, “Starting with presenting a major direction at this Korean Neurosurgical Society Spring Scientific Meeting, we plan to actively promote ‘Selvein Injection’ to lead the market.”

This content was produced with the assistance of AI translation services.